



# Medical Marijuana: What a Physician Needs to Know

Kevin P. Hill, M.D., M.H.S.  
6/18/14, MMS  
Medical Marijuana Symposium

*McLean Hospital Division of Alcohol and Drug Abuse*  
*khill@mclean.harvard.edu*  
*@DrKevinHill*

Supported by NIDA K99/R00 DA029115 (Kevin P. Hill, MD, MHS, PI) and the Adam Corneel Young Investigator Fellowship from McLean Hospital to Dr. Hill.



## Disclosure

I have no financial relationship with a commercial entity producing health-care related products and/or services.




## Three Areas of Focus

- Clinical work: McLean Substance Abuse consultation service, private practice.
- Clinical research: 3 clinical trials (2 marijuana, 1 tobacco cigarettes).
- Educational outreach: Science vs. public perception, official community partner to Boston Public Schools, book on marijuana to be released in early 2015.



## In The Middle





# Marijuana Use: Scope of the Problem




## Context of Current Laws- National Statistics

- Over 18 million Americans used marijuana in the past year.
- Powerful messages– medical marijuana, legalization, pop culture.
- Some messages off the mark, contribute to gap between science and public perception.




## Development of Problems: About 9% of users may become dependent; 1 in 6 who start use in adolescence

Estimated Prevalence of Dependence Among Users



## 12<sup>th</sup> Graders' Past Year Marijuana Use vs. Perceived Risk of Occasional Marijuana Use



SOURCE: University of Michigan, 2013 Monitoring the Future Study



## Why So Complicated?

- Can't paint with a broad brush.
- Many misguided by their own experiences.
- Math can be tricky.



## Marijuana Myths

- Not harmful
- Not addictive
- No withdrawal




## IT IS HARMFUL!




- Early onset → poor cognitive function, IQ decline (Pope 2003, Gruber 2011, Meier 2012)
- ↑ anxiety (Crippa 2009)
- ↑ depression (Degenhardt 2003)
- ↑ risk of psychosis (Kuepper 2011, Large 2011)



## IT IS ADDICTIVE!




Drugs of abuse increase DA in the Nucleus Accumbens....triggers the neuroadaptations that result in addiction?





## There is Withdrawal!

(Vandrey et al., 2005; Vandrey et al. 2008, Budney et al., 2009)




## Marijuana Policy in the Commonwealth: A Trend Toward Increased Access



## 2008- Decriminalization of less than an ounce in MA



## 2012 MMJ Ballot Initiative







## Legalization in 2016?





# State of the Science: Medical Marijuana



## Pharmacology of Marijuana

- 60 pharmacologically-active cannabinoids.
- THC: euphoria, anti-inflammatory, psychosis.
- CBD: non-psychoactive, anti-anxiety, antipsychotic?
- Anti-oxidant, neuroprotective?



## Medical Marijuana-Composition

- Very different from the marijuana of the 60s,70s,80s- many are misguided by their own experiences.
- Average THC content 13%, but upper 20s possible.
- Strains adjust THC:CBD, but high THC is what sells.



## FDA-Approved Cannabinoids

- Dronabinol (Marinol)- oral THC.
- Nabilone (Cesamet)- CB<sub>1</sub> agonist.
- FDA-Approved for 1)Nausea and vomiting associated with chemotherapy 2) Appetite stimulation in wasting illnesses like AIDs.
- Maybe CBD, and cannabis therefore, offer some things that dronabinol and nabilone don't.



## Medical Indications According to Laws

- MA- “debilitating conditions.”
- Laws in various states--Cancer, glaucoma, AIDs, Hep C, ALS, Crohn’s Disease, Parkinson’s, multiple sclerosis.
- Keep in mind that data suggests that the majority of people with medical marijuana cards do not have one of the above conditions.



## Medical Indications According to Science

- Over 50 clinical trials of cannabinoids, including marijuana.
- Aside from the FDA indications for dronabinol and nabilone, the best data (approx. half of studies positive) are for chronic pain, neuropathic pain, and spasticity associated with Multiple Sclerosis.
- Other data is not positive.



## Kleber and DuPont, AJP, 2012

- MMJ laws challenge physicians to recommend use of a schedule I illegal drug of abuse with no scientific approval, dosage control, or quality control.
- Opposed by APA, AMA, ASAM.



## 3 Reasons You Need to Know about MMJ

- 1 Your patients will ask about it.
- 2 Your colleagues will ask about it.
- 3 You may be asked to consult on whether a colleague should certify one of their patients for MMJ.

*Whatever you decide, make informed decisions*



# **MMJ: What is in place NOW**



## **Medical Marijuana Details**

- Not covered by insurance.
- Recommendations cannot be used to buy marijuana in other states.
- Many doc-in-a-box, stand-alone clinics.



## **Regulations: Some good, some not so good**

- Thorough efforts that addressed most of the key issues.
- MMTC qualifications, use of PMP.
- Several points that could stand modification (age limits, advertising, edible products).



## **Top 3 Issues**



## Issue #1

- MA: 60 day supply = 10 ounces
- BUT 725.010 “A certifying physician may determine and certify that a qualifying patient requires an amount of marijuana exceeding ten ounces as a 60-day supply and shall document the amount and the rationale in the medical record and in the written certification. For that qualifying patient, that amount of marijuana constitutes a 60-day supply.”
- My studies: 2.1 oz. per month  $\pm$  3.0 oz.



## Issue #2

- MA: “Debilitating medical condition” such as cancer, glaucoma, AIDS or HIV, Hep C, Crohn’s, Parkinson’s, MS...
- Or other conditions as determined in writing by physician.
- Suggestion: other conditions upon approval by DPH (like medication PAs).





## Issue #3

- Automatic hardship for MassHealth, SSI patients.
- They are granted hardship to grow their own.
- Will this lead to unintended consequences?



## Hypothetical Scenario

- Mr. A, a patient on MassHealth, gets MMJ card to treat his migraine headaches.
- He smokes  $\frac{1}{4}$  ounce a week, or 2 ounces per 60 days.
- He recognizes that he can grow another 8 ounces (approximate street value of \$3200, or \$19,200 per year).



# **MMJ: Suggestions on what you should do**



## **If a patient asks about MMJ**



## Policies

- Facility/group practice/individual practice-policy can be helpful.
- Clear, united front on a controversial topic.
- We have discussed a MMJ policy at McLean that addresses key questions.



## Does the scientific literature support the use of marijuana as medicine?

- Right now, no.
- Some positive studies, more negative studies, more research needed to earn FDA approvals.
- Are there better, safer alternatives?
- No major medical organization (AMA, APA, ASAM, AACAP) supports the use of medical marijuana.



## **Marijuana as medicine? Part 2**

- MMJ circumvents FDA process.
- Safety: Potency, purity, composition.
- Doctor-patient relationships are constrained by time already, will MMJ collaborations be held to an even lower standard?



**I have read through the scientific evidence, but I still would like to pursue a recommendation for medical marijuana.  
How can I do this?**

- By definition, our psychiatric patients are unlikely candidates for MMJ.
- Psychiatrists are probably not treating them for conditions that might benefit from MMJ.
- Referral to oncologist, specialist, or other physician that might treat the debilitating condition.



## Yes, you qualify...

- Discussion, documentation of pros and cons (impaired driving, mood).
- Written recommendation.
- More frequent visits- monitor for side effects.



## My son/daughter/spouse wants medical marijuana, but I worry that he/she wants it because he/she is already addicted to it. What can I do?

- This is an area where we are better equipped to help.
- Lengthier phone conversation and likely consultation.
- Direct to appropriate educational resources  
(<http://www.drugabuse.gov/publications/drugfacts/marijuana>)



## If a colleague asks about MMJ



## Consults on Question of Certification

- You can “just say no”—but I hope you won’t. This is an opportunity to provide a service.
- Assess substance abuse risk.
- Careful history— always keep in mind that you may be taking the most thorough history ever for this patient.



## Consults on Question of Certification, Part 2

- Treat this as you would the question of other addictive medications (stimulants, benzos) in this patient.
- History of drug use disorders, psychiatric co-morbidities, psychosocial stressors.
- DPH criteria/criteria from other state.



## Other Issues

- How do facilities handle MMJ?
- Programs funded by DPH Bureau of Substance Abuse Services cannot refuse admission to patients with MMJ recommendation.
- Use not allowed on site. Use dronabinol or nabilone as a substitute.



## If You Don't Know What To Do?

- Never worry alone.
- Addiction psychiatrists, McLean, etc.



## Policy Ahead of the Science

- Feasible, but implementation thus far has not inspired confidence.
- We can work to get answers to inform choices or we can continue to sling rhetoric back and forth.





## Critical Period

- Trends are ominous- MTF data.
- We can provide a service to colleagues by being informed and thoughtful on this topic.
- How we respond to MMJ can have an impact on these rates.
- There still may be an opportunity to shape the MMJ regulations.



## Acknowledgments

- Alan Wartenberg
- Max Hurley-Welljams-Dorof
- Roger Weiss



# Questions?

Recruiting line:  
617 855 3823



## Nabilone for Cannabis Dependence

- Possible agonist pharmacotherapy for cannabis dependence (not unlike methadone or buprenorphine for heroin and nicotine patch for tobacco).
- Funded by NIDA and Adam Corneel Young Investigator Fellowship.
- Clinicaltrials.gov NCT 01347762, IND granted by the FDA.



## Synthetics

- K2, Spice, and a host of other names.
- Synthetic cannabinoids sprayed onto herbs.
- Synthetic Drug Abuse Prevention Act of 2012- makers a step ahead.
- Access and groups who will be tested.




## **More Dangerous Than Regular Marijuana?**

- Never really sure what you are getting.
- Not detectable with standard urine testing.
- More likely to precipitate psychosis?



## **State of the Science: Treatment**



Current Treatment Options in Psychiatry  
DOI 10.1007/s40501-014-0013-6

Substance Use Disorders (RD Weiss and HS Connery, Section Editors)

## Behavioral Interventions and Pharmacotherapies for Cannabis Use Disorder

Aaron J. Bobb, MD<sup>1,2,\*</sup>  
Kevin P. Hill, MD, MHS<sup>1,2</sup>

**Address**  
<sup>1</sup>Division of Alcohol and Drug Abuse, McLean Hospital, 115 Mill Street, Belmont,  
MA 02478, USA  
abobb@partners.org  
<sup>2</sup>Department of Psychiatry, Harvard Medical School, Boston, MA, USA



## What does treatment look like?

- Medical detox is not necessary.
- 30 days of “rehab” is unlikely.
- Get prospective patient to talk to somebody.
- Readiness/alliance work.



## No FDA-Approved Medications (Yet)

- Gabapentin, N-acetylcysteine– promising medications with positive results thus far.
- Other work being done currently.
- My studies are looking at nabilone, dronabinol, and pending funding, CBD.



## Legalization

- WA, CO, likely on the ballot in MA in 2016.
- Addiction vs. Harmless/Personal Freedom/Taxes
- 58% of Americans favor legalization.



## Once again, the science suggests we are not ready

- Safety - drugged driving.
- Need a marijuana equivalent of .08 BAC AND technology to test for it in the field.
- Addiction numbers in WA and CO, but they did not set up to efficiently track these outcomes.